









Markets
/
Stocks
/
nasdaq-fdmt
/

4D Molecular Therapeutics Inc

FDMT

10.500USD

-0.420-3.85%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

490.35MMarket Cap

LossP/E TTM



4D Molecular Therapeutics Inc

10.500

-0.420-3.85%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of 4D Molecular Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

4D Molecular Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

67 / 407

Overall Ranking

183 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

30.714

Target Price

+192.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

4D Molecular Therapeutics Inc Highlights

StrengthsRisks

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 37.00K.

Fairly Valued

The company’s latest PE is -2.97, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.60M shares, decreasing 30.22% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 27.93K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.89.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.24, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 15.00K, representing a year-over-year increase of 200.00%, while its net profit experienced a year-over-year increase of 56.38%.

Score

Industry at a Glance

Previous score

7.24

Change



Financials

7.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

4D Molecular Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.76, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.97, which is -73.49% below the recent high of -0.79 and -368.19% above the recent low of -13.92.

Score

Industry at a Glance

Previous score

7.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for 4D Molecular Therapeutics Inc is 31.00, with a high of 40.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

32.500

Target Price

+209.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

4D Molecular Therapeutics Inc

FDMT

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.89, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 12.39 and the support level at 8.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.06

Change

-0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.392

Neutral

RSI(14)

52.345

Neutral

STOCH(KDJ)(9,3,3)

24.252

Sell

ATR(14)

1.003

High Vlolatility

CCI(14)

-103.136

Sell

Williams %R

77.065

Sell

TRIX(12,20)

1.054

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

10.780

Sell

MA10

11.237

Sell

MA20

10.814

Sell

MA50

8.912

Buy

MA100

7.012

Buy

MA200

5.481

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 86.96%, representing a quarter-over-quarter decrease of 13.12%. The largest institutional shareholder is The Vanguard, holding a total of 2.74M shares, representing 5.86% of shares outstanding, with 5.11% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

4.63M

+1.49%

RA Capital Management, LP

4.56M

Goldman Sachs & Company, Inc.

3.74M

-0.21%

Novo Holdings A/S

2.00M

+2.56%

BlackRock Institutional Trust Company, N.A.

3.12M

-11.76%

The Vanguard Group, Inc.

Star Investors

2.74M

-0.75%

Janus Henderson Investors

1.75M

-7.27%

Kirn (David)

1.66M

-0.02%

Federated MDTA LLC

1.65M

+33.10%

Millennium Management LLC

1.48M

-9.20%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.33, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.95. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.